The 2022 Tandem Meetings | Current treatment options and emerging strategies in MCL
Manali Kamdar, MD, University of Colorado Cancer Center, Aurora, CO, provides an overview of the current treatment paradigm in mantle cell lymphoma (MCL) and outlines emerging therapeutic strategies for this disease. The treatment landscape of MCL has dramatically changed over the past few years with the advent of BTK inhibitors (BTKi) for patients who relapse after frontline therapy, as well as with the approval of brexucabtagene autoleucel (brexu-cel). Pirtobrutinib is now used for patients who relapse after BTKi. Nevertheless, there remains an unmet need for patients with high-risk disease as they have a suboptimal response to BTKi. CAR-T therapy has emerged as a promising alternative for those patients and lisocabtagene maraleucel (liso-cel) is currently being explored in a trial that has reported encouraging safety and efficacy results so far. Bispecific antibodies such as glofitamab are also being evaluated in R/R MCL. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.
Disclosures
Research Support/Funding: TG Therapeutics, Genentech, Novartis
Consultancy: AbbVie, AstraZeneca, Celgene/ Bristol-Myers Squibb, Adaptive Biotechnologies, ADC therapeutics, Beigene, Genentech, Impact bio
Speaker’s bureau: SeaGen
DMC: Celgene , Genentech
